Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)

Login to access report north_east
Contact sales account_box

Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often cumbersome. Recombinant human growth hormone (rhGH) has been the mainstay treatment for GHD since 1985. The current landscape for rhGH therapy is very competitive; several products are approved, and only a few agents are in late-phase clinical trials. Each of the products in development aims to improve the frequency of dosing, thereby reducing the burden on patients.

Questions answered

  • What is the prevalence of GHD? How are U.S. GHD patients managed?
  • What are the key areas of unmet need and opportunities in the treatment of GHD?
  • Which therapies are in late-phase development for GHD? What is the potential impact of new launches, and how will these therapies affect future opportunity in the treatment of GHD?
  • What are the key drivers of, and limitations on, the market today and in the future?

Product description

Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Geography: United States

Primary research: Three KOL interviews from March 2023

Key companies covered: Novo Nordisk, Eli Lilly, Roche / Genentech, Pfizer, Sandoz, Merck KGaA, Ferring, Ascendis Pharma, Lumos Pharma

Key drugs covered: Norditropin, Genotropin / Genotropin MiniQuick, Omnitrope, Humatrope, Nutropin, Saizen, Zomacton, Skytrofa, Somapacitan (Sogroya), Somatrogon (Ngenla), Ibutamoren mesylate (LUM 201)

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east